IN THE NEWS

ASSESSMENT OF NEEDLE-FREE DISPOSABLE-SYRINGE JET INJECTOR (DSJI) ID DOSE-SPARING OF PANDEMIC A H1N1 INFLUENZA VACCINE.

This study will evaluate the immunological response and the safety profiles of seasonal, inactivated vaccine which contains in its composition the
A/California/7/2009 H1N1 "pandemic" influenza virus, delivered via ID in reduced dose (0,1 mL) and (0,2 mL), and via IM in full dose (0,5 mL)
delivered with needle-free, disposable-syringe jet injector, and control group with via IM in full dose (0,5 mL) delivered syringes and needles in
subjects from 42 to 60 years old.

June 20, 2012

SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF INACTIVATED TRIVALENT SEASONAL INFLUENZA VACCINE ADMINISTERED WITH A NEEDLE-FREE DISPOSABLE-SYRINGE JET INJECTOR.

Publication, in the Vaccine Journal, of the results of a Clinical study on the LectraJet® M3 RA conducted by the Division of Geomedicine at the Center for Vaccine Development, University of Maryland.

October 8, 2011

WORLD HEALTH ORGANIZATION: INTRADERMAL DELIVERY OF VACCINES

September 2009

A review of the literature and the potential for development for use in low- and middle- income countries

 

© 2019 by D'Antonio Consultants International, Inc.